Menu
  • Join
  • Login
  • Contact
 

Search abstracts


COMPARISON OF THE EFFICACY AND SAFETY OF INNOVATOR RITUXIMAB AND RITUXIMAB BIOSIMILAR

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: ISEZAKI, Tatsuya (Japan)
  • Co-author(s): Tatsuya Isezaki: Department of Pharmacy, Kameda medical center, Chiba, Japan
    Keiko Miyagawa: Department of Pharmacy, Kameda medical center, Chiba, Japan
    Kentaro Narita: Department of Hematology, Kameda medical center, Chiba, Japan
    Ryohkan Funakoshi: Department of Pharmacy, Kameda medical center, Chiba, Japan
  • Abstract:

    Background

    Biosimilars are products that are equivalent to original bio-pharmaceuticals. The use of biosimilars increases medical access to useful treatments, improves the quality of treatment, and reduces costs. The inclusion criteria for the rituximab biosimilar clinical trials were limited to patients with follicular lymphoma, and an analysis of ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses